OCGN Ocugen
- 1.6600
- +0.0900+5.73%
Ocugen News
Ocugen | 8-K: Current report
Ocugen | S-3: Registration statement for specified transactions by certain issuers
Ocugen | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Ocugen | 8-K: Ocugen Announces U.S. Food and Drug Administration Approval of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
Ocugen | 8-K: Ocugen Reports Year End 2023 Financial Results and Provides Corporate Update
Ocugen | 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Ocugen | NT 10-K: Others
Ocugen | 8-K: United States Court of Appeals for the Third Circuit Affirmed the Decision of Consolidated Securities Class Action Lawsuit
Ocugen | 8-K: Director Patrick Grady Will Not Run For Re-Election At The 2024 Shareholder Meeting
Ocugen | 8-K: Ocugen Announces Appointment of Huma Qamar as Chief Medical Officer
Ocugen | 8-K: Presentation of an In-Person Clinical Showcase at the Nasdaq Market Site in Times Square
Ocugen | 8-K: Ocugen Grants Performance-Based Restricted Stock Units to Incentive Recipients
Ocugen | 8-K: Ocugen Gains FDA Alignment on Key Aspects of OCU400 Modifier Gene Therapy Pivotal Phase 3 Study Design
Ocugen | 8-K: Ocugen Posted Presentation of Courageous Innovation
Ocugen | 8-K: Ocugen Provides Business Update with Third Quarter 2023 Financial Results
Ocugen | 8-K: Current report
Ocugen | 8-K: Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Ocugen | 8-K: Ocugen Board of Directors Appointed Michael Breininger as the Interim Chief Accounting Officer and Principal Financial Officer
Ocugen | 8-K: Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400
Ocugen | 8-K: Earnings Release Presentation
Analysis
Price Target
No Data
